Dupilumab-associated head and neck dermatitis shows a pronounced type 22 immune signature mediated by oligoclonally expanded T cells

Abstract Dupilumab, an IL4R-blocking antibody, has shown clinical efficacy for atopic dermatitis (AD) treatment. In addition to conjunctivitis/blepharitis, the de novo appearance of head/neck dermatitis is now recognized as a distinct side effect, occurring in up to 10% of patients. Histopathologica...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Christine Bangert, Natalia Alkon, Sumanth Chennareddy, Tamara Arnoldner, Jasmine P. Levine, Magdalena Pilz, Marco A. Medjimorec, John Ruggiero, Emry R. Cohenour, Constanze Jonak, William Damsky, Johannes Griss, Patrick M. Brunner
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Nature Portfolio 2024-04-01
Sarja:	Nature Communications
Linkit:	https://doi.org/10.1038/s41467-024-46540-0
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!